Tag: immune checkpoint inhibitors

1. Co-occurrences could be clustered together into 7 clusters based on the predominant organ system affected; endocrine, cutaneous, respiratory, gastrointestinal, ...

1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no ...

1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...

1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events ...

1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...

1. Stereotactic body radiotherapy in addition to immune checkpoint inhibitors has similar progression-free survival to immune checkpoint inhibitors alone, with ...

1. Median overall survival was longer in patients receiving steroid-only treatment for adverse events associated with immune response. 2. Patients ...